Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers

Biotec Pharmacon ASA133 enrolled

Overview

Evaluation of efficacy and safety of SBG vs placebo in the treatment of chronic diabetic foot ulcers.

The objective of this study is to evaluate efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) on chronic diabetic foot ulcers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

133

Conditions

Diabetes Diabetic Ulcer

Interventions

SBGDRUG

Solution for topical use

Placebo ComparatorDRUG

Solutin for topical use

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with chronic diabetic foot ulcer Exclusion Criteria: * Insufficient nutritional status, renal function or diabetes control

Locations (1)

Universidad Complutense de Madrid

Madrid, Spain

Outcomes

Primary Outcomes

Compare the proportion of patients in the two arms who have complete healing of target ulcer

Time frame: Maximum 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.